Influenza vaccine: Patients receive injection of 0.5ml influenza vaccine
Placebo: Patients will receive injection of 0.5ml PBS
Study summary
The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:
* Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?
* Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis?
If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.
Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. ACS patient aged from 18 to 80 years.
2. Volunteer for the study and written informed consent.
Exclusion Criteria:
1. Participate in any drug clinical trials within 3 months.
2. Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.
3. Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).
4. Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix).
5. Patients refused to comply with the requirements of this study to complete the research work.
6. Patients Received influenza vaccination within 1 year.
7. Patients with contraindications for influenza vaccination.
Primary outcome measure(s)
Composite endpoint of cardiovascular death, myocardial infarction or stroke — 12 months The number of participants with cardiovascular death, myocardial infarction or stroke (first occurring) till 12 months.
Trial sites (1)
Facility
City
Region
Status
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.